MDFI (MyoD family inhibitor) is a multifunctional regulatory protein with roles spanning myogenic differentiation, mechanosensation, and cardiac pathology. Primarily, MDFI inhibits myogenic transcription factors by sequestering MyoD family members in the cytoplasm and masking their nuclear localization signals, thereby repressing myogenesis 1. Beyond myogenic regulation, MDFI functions as an auxiliary subunit of PIEZO1/2 mechanosensitive channels through a lipidated C-terminal helix that inserts into the channel pore module, modulating channel inactivation kinetics 1. This PIEZO-regulatory function has therapeutic implications: MDFIC2, a related family member, when upregulated via gene therapy, attenuates mechanical allodynia in neuropathic pain models by slowing PIEZO channel kinetics 2. In skeletal muscle, elevated MDFI promotes fast-to-slow fiber type conversion via calcium signaling pathway activation, enhancing mitochondrial biogenesis and aerobic metabolism 3. Clinically, MDFI exhibits tissue-dependent cancer associations: it is upregulated in colorectal, breast, ovarian, and prostate cancers where it promotes growth, but downregulated in gastric cancer where it may serve as a prognostic biomarker 4, 5. In cardiac pathology, the miR-128/MDFI axis regulates Wnt/β-catenin signaling, with MDFI suppression promoting cardiomyocyte proliferation and cardiac repair in heart failure 6.